Technical Analysis for LJPC - La Jolla Pharmaceutical Company

Grade Last Price % Change Price Change
grade F 6.02 -0.50% -0.03
LJPC closed down 0.5 percent on Friday, November 15, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical LJPC trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -0.50%
Down 3 Days in a Row Weakness -0.50%
Down 4 Days in a Row Weakness -0.50%
Oversold Stochastic Weakness -0.50%
Expansion Breakdown Bearish Swing Setup -4.44%

Older signals for LJPC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company's products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Medication Chronic Kidney Disease Peptide Hormones Proteins Lectins Galectin Galectin 3 Hepatorenal Syndrome
Is LJPC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.44
52 Week Low 5.01
Average Volume 292,215
200-Day Moving Average 7.9716
50-Day Moving Average 8.5421
20-Day Moving Average 7.172
10-Day Moving Average 6.72
Average True Range 0.4748
ADX 35.55
+DI 11.8891
-DI 32.076
Chandelier Exit (Long, 3 ATRs ) 7.525599999999999
Chandelier Exit (Short, 3 ATRs ) 7.3444
Upper Bollinger Band 8.6247
Lower Bollinger Band 5.7193
Percent B (%b) 0.1
BandWidth 40.510318
MACD Line -0.6238
MACD Signal Line -0.5632
MACD Histogram -0.0606
Fundamentals Value
Market Cap 133.18 Million
Num Shares 22.1 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -1.18
Price-to-Sales 5475.91
Price-to-Book 5.28
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.78
Resistance 3 (R3) 6.84 6.64 6.65
Resistance 2 (R2) 6.64 6.45 6.61 6.61
Resistance 1 (R1) 6.33 6.33 6.23 6.27 6.57
Pivot Point 6.14 6.14 6.09 6.11 6.14
Support 1 (S1) 5.83 5.94 5.73 5.77 5.47
Support 2 (S2) 5.63 5.82 5.60 5.43
Support 3 (S3) 5.32 5.63 5.39
Support 4 (S4) 5.26